Prophylactic glycopyrrolate reduces hypotensive responses in TURP patients during spinal anesthesia
Phase 4
Completed
- Conditions
- TURP surgery
- Registration Number
- TCTR20191105001
- Lead Sponsor
- Sawanpracharak Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 54
Inclusion Criteria
ASA II patient who has TURP surgery
Exclusion Criteria
glaucoma, hyperthyroid , cardiovascular disease, pulmonary disease , morbid obesity , renal or hepatic dysfunction , neuromuscular disease, coagulopathy
used premedication in surgery day
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficiency of glycopyrolate 0.2 mg during sugery until discharge cardiovascular effect
- Secondary Outcome Measures
Name Time Method cardiovascular effect during sugery until discharge blood presure, heart rate, total fluid, total blood loss, total ephedrine use
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain glycopyrrolate's effect on hypotension during spinal anesthesia in TURP patients?
How does prophylactic glycopyrrolate compare to vasopressor agents like phenylephrine in TURP spinal anesthesia trials?
Are cholinergic receptor polymorphisms predictive of hypotension response to glycopyrrolate in urological surgeries?
What adverse events are associated with glycopyrrolate use in elderly TURP patients undergoing spinal anesthesia?
Do combination therapies involving glycopyrrolate and neostigmine improve hemodynamic stability during TURP procedures?